VSIG4 and diffuse large B-cell lymphoma: Additionally, VSIG4+ DLBCL cases showed a higher prevalence of non-GCB/ABC COO subtypes, MYC+/BCL-2+ double-expression phenotypes, mutations in PIM1, ETV6, and CD70, and a trend towards a higher MCD subtype frequency (43.3% vs 17.6%).